Your search has found 1178 articles in the database for the term 'Cognition (for those taking standard Alzheimer’s Disease medication)'
Click
here to filter this large number of results.
Validation of Alzheimer’s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI)
Buerger, Katharina,
Frisoni, Giovanni,
Uspenskaya, Olga,
Ewers, Michael,
Zetterberg, Henrik,
Geroldi, Cristina,
Binetti, Giuliano,
Johannsen, Peter,
Rossini, Paolo Maria,
Wahlund, Lars-Olof,
Vellas, Bruno,
Blennow, Kaj,
Hampel, Harald
...Background: Alzheimer’s Disease Neuroimaging Initiatives (“ADNI”) aim to validate neuroimaging and biochemical markers of Alzheimer’s disease (AD). Data of the pilot European-ADNI (E-ADNI) biological marker programme of cerebrospinal fluid...
Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer’s disease: the omega-3 Alzheimer’s disease study
Faxén Irving, Gerd,
Freund-Levi, Yvonne,
Eriksdotter-Jönhagen, Maria,
Basun, Hans,
Brismar, Kerstin,
Hjorth, Erik,
Palmblad, Jan,
Vessby, Bengt,
Vedin, Inger,
Wahlund, Lars-Olof,
Cederholm, Tommy
...Objectives: To study the effects of omega (Omega)-3 fatty acid (FA) supplements on weight and appetite in patients with mild to moderate Alzheimer’s disease (AD) in relation to inflammatory...
Women have farther to fall: gender differences between normal elderly and Alzheimer’s disease in verbal memory engender better detection of Alzheimer’s disease in women
Chapman, Robert M.,
Mapstone, Mark,
Gardner, Margaret N.,
Sandoval, Tiffany C.,
McCrary, John W.,
Guillily, Maria D.,
Reilly, Lindsey A.,
DeGrush, Elizabeth
...We analyzed verbal episodic memory learning and recall using the Logical Memory (LM) subtest of the Wechsler Memory Scale-III to determine how gender differences in AD compare to those...
Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia
Claxton, Amy,
Baker, Laura D.,
Hanson, Angela,
Trittschuh, Emily H.,
Cholerton, Brenna,
Morgan, Amy,
Callaghan, Maureen,
Arbuckle, Matthew,
Behl, Colin,
Craft, Suzanne
...[Correction Notice: An Erratum for this article was reported in Vol 45(4) of Journal of Alzheimer’s Disease (see record [rid]2015-17286-023[/rid]). In the original article, Tables 1 and 2 were...
Vitamin E and memantine in Alzheimer’s disease: clinical trial methods and baseline data
Dysken, Maurice W.,
Guarino, Peter D.,
Vertrees, Julia E.,
Asthana, Sanjay,
Sano, Mary,
Llorente, Maria,
Pallaki, Muralidhar,
Love, Susan,
Schellenberg, Gerard D.,
McCarten, J. Riley,
Malphurs, Julie,
Prieto, Susana,
Chen, Peijun,
Loreck, David J.,
Carney, Sara,
Trapp, George,
Bakshi, Rajbir S.,
Mintzer, Jacobo E.,
Heidebrink, Judith L.,
Vidal-Cardona, Ana,
Arroyo, Lillian M.,
Cruz, Angel R.,
Kowall, Neil W.,
Chopra, Mohit P.,
Craft, Suzanne,
Thielke, Stephen,
Turvey, Carolyn L.,
Woodman, Catherine,
Monnell, Kimberly A.,
Gordon, Kimberly,
Tomaska, Julie,
Vatassery, Govind
...Background: Alzheimer’s disease (AD) has been associated with both oxidative stress and excessive glutamate activity. A clinical trial was designed to compare the effectiveness of (i) alpha-tocopherol, a vitamin...
Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle Study: Collaboration with the Alzheimer’s Disease Neuroimaging Initiative
Ellis, Kathryn A.,
Rowe, Christopher C.,
Villemagne, Victor L.,
Martins, Ralph N.,
Masters, Colin L.,
Salvado, Olivier,
Szoeke, Cassandra,
Ames, David
...The Australian Imaging Biomarkers and Lifestyle (AIBL) study is a longitudinal study of 1112 volunteers from healthy, mild cognitive impairment, and Alzheimer’s disease (AD) populations who can be assessed...
Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer’s disease and cerebrovascular disease: a pilot study
Sakurai, Hirofumi,
Hanyu, Haruo,
Sato, Tomohiko,
Kume, Kazumasa,
Hirao, Kentaro,
Kanetaka, Hidekazu,
Iwamoto, Toshihiko
...Aim: It remains unknown whether antiplatelet agents have a preventive effect on cognitive decline in patients with Alzheimer’s disease (AD). We investigated the effects of cilostazol, an antiplatelet agent...
Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy
Miyoshi, F.,
Ogawa, T.,
Kitao, S.- i.,
Kitayama, M.,
Shinohara, Y.,
Takasugi, M.,
Fujii, S.,
Kaminou, T.
...Background and Purpose: Progressive changes in the substantia nigra pars compacta and locus ceruleus of patients with Parkinson disease and Alzheimer disease visualized by neuromelanin MRI and cardiac postganglionic...
A phase 3 trial of semagacestat for treatment of Alzheimer’s disease
Doody, Rachelle S.,
Raman, Rema,
Farlow, Martin,
Iwatsubo, Takeshi,
Vellas, Bruno,
Joffe, Steven,
Kieburtz, Karl,
He, Feng,
Sun, Xiaoying,
Thomas, Ronald G.,
Aisen, Paul S,
Siemers, Eric,
Sethuraman, Gopalan,
Mohs, Richard
...cognitive subscale of the Alzheimer’s Disease Assessment Scale for cognition (ADAS-cog), on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment, and changes in functioning...